Thiosemicarbazone compounds are a class of multidentate ligands that contain potential binding sites for a wide variety of metal ions such as iron and copper. This work will present the synthesis of a series of new, never before synthesized, 2-acetyl-3-ethylpyrazine thiosemicarbazone compounds (AEPZ-TSC's). These new compounds are potential anti-cancer agents, as they most likely interfere with ribonucleotide reductase, an iron-containing enzyme used by cells to produce DNA. They are structurally similar to Triapine, which has undergone Phase 2 clinical trials. The work includes the structural characterization of the new compounds by 1H NMR spectroscopy. The purpose of this project was to synthesize, characterize, and determine the minimum inhibitory concentration (MIC) of this series of compounds for four bacteria (Bacillus subtilis, Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa), two yeast (Candida albicans and Saccharomyces cerevisiae), and a mold (Aspergillus niger) to determine the indication of biological activity and anti-proliferation capacity.

Properties of a new series of acetyl-ethyl-pyrazine thiosemicarbazones (ACEP-TSC's) and their copper(II) complexes

245th National Meeting (2013)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.